VivoSim Labs, Inc. income statement VIVS

Annual Quarterly

In fiscal 2026, which ended Mar 31, 2026, VivoSim Labs, Inc. reported revenue of $131,000, down 9.0% from the year before. It recorded a net loss of $13.8 million. The operating loss came to $11.5 million, an operating margin of -8768.7%. Diluted earnings per share were -$5.35. Across the 9 fiscal years shown, revenue shrank from $4.2 million in fiscal 2017 to $131,000 in fiscal 2026, about 35.2% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2027 Jun 30, 2026	FY 2026 Mar 31, 2026	FY 2025 Mar 31, 2025	FY 2024 Mar 31, 2024	FY 2023 Mar 31, 2023	FY 2022 Mar 31, 2022	FY 2021 Mar 31, 2021	FY 2020 Mar 31, 2020	FY 2019 Mar 31, 2019	FY 2018 Mar 31, 2018	FY 2017 Mar 31, 2017
Revenue	—	0 -9.0%	0 +32.1%	0 -70.5%	0 -75.3%	2	0 -100.0%	2 -29.0%	3 -32.8%	5 +8.8%	4 +185.2%
Cost of revenue	—	0 -100.0%	0	—	—	—	0 -100.0%	0 -40.0%	0 -50.0%	1 +4.6%	1
Gross profit	—	0 -5.8%	0	—	—	—	0 -100.0%	2 -26.8%	3 -28.1%	4 +10.0%	3
Research and development	—	4 -16.6%	5 -8.6%	5 -38.1%	9 +167.6%	3 +201.0%	1 -79.1%	5 -64.2%	15 -17.8%	18 -8.1%	20 +8.5%
Selling, general and administrative	—	7 -3.9%	8 -20.3%	10 +5.2%	9 -4.6%	10 -38.6%	16 -12.9%	18 +19.4%	15 -27.6%	21 -6.3%	22 +0.8%
Operating expenses	—	12 -8.9%	13	—	—	—	17	—	—	—	42
Operating income	—	-11 +8.9%	-13 +16.4%	-15 +14.9%	-18 -54.5%	-11 +31.8%	-17 +21.6%	-21 +21.3%	-27 +22.7%	-35 +8.6%	-39 +0.2%
Interest expense	—	0 +20.0%	0	—	—	—	—	—	—	—	—
Other income (expense)	—	-2 -123.2%	10 +2329.3%	0 -12.0%	0 +1336.4%	0 +1550.0%	0 -99.9%	3 +331.0%	1 +36.6%	0 +211.3%	0 +112.7%
Pretax income	—	-14	—	—	—	—	—	—	—	—	—
Income tax	—	0 +0.0%	0 +0.0%	0 +0.0%	0 +0.0%	0 +0.0%	0 +0.0%	0 -33.3%	0 +50.0%	0 -91.3%	0 +666.7%
Net income	—	-14 -456.4%	-2 +83.0%	-15 +15.0%	-17 -50.8%	-11 +32.0%	-17 +10.1%	-19 +29.8%	-27 +23.5%	-35 +9.5%	-38 +0.3%
Basic EPS	—	-5.35 -214.7%	-1.70 +91.2%	-19.25 -872.2%	-1.98	—	—	—	—	—	—
Diluted EPS	—	-5.35 -214.7%	-1.70 +91.2%	-19.25 -872.2%	-1.98	—	—	—	—	—	—
Weighted average shares, basic	—	3 +76.8%	1 +92.1%	1 -91.3%	9	—	—	—	—	—	—
Weighted average shares, diluted	—	3 +76.8%	1 +92.1%	1 -91.3%	9	—	—	—	—	—	—
Other measures
Depreciation and amortization	—	0 -19.2%	0 -5.0%	0 -4.4%	0 +106.3%	0 +246.3%	0 -96.4%	1 +16.5%	1 -22.7%	1 +10.3%	1 +41.0%
EBITDA	—	-11 +8.7%	-12 +16.6%	-15 +15.1%	-17 -53.8%	-11 +32.5%	-17 +17.4%	-20 +22.7%	-26 +22.7%	-34 +9.1%	-37 +1.1%
Interest coverage	—	-957.25x	-1,261.60x	—	—	—	—	—	—	—	—
Margins
Gross margin	—	100.00%	96.53%	—	—	—	—	86.34%	83.82%	78.28%	77.40%
Operating margin	—	-8,768.70%	-8,761.11%	-13,840.37%	-4,792.16%	-765.27%	—	-977.91%	-882.37%	-766.26%	-911.94%
Pretax margin	—	-10,565.65%	—	—	—	—	—	—	—	—	—
Profit margin	—	-10,567.18%	-1,727.78%	-13,459.63%	-4,664.59%	-763.20%	—	-852.00%	-861.70%	-756.09%	-908.91%
EBITDA margin	—	-8,604.58%	-8,576.39%	-13,583.49%	-4,712.97%	-755.80%	—	-925.91%	-850.66%	-738.74%	-884.78%

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: VIVS (Nasdaq)
Fiscal year ends: March 31
Incorporated in: DE
Headquarters: San Diego, CA
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1497253
Former names: ORGANOVO HOLDINGS, INC. (until Apr 23, 2025); REAL ESTATE RESTORATION & RENTAL, INC. (until Oct 31, 2011)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.